Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • In persons coinfected with HIV and HCV, the prevalence of steatosis ranges from 40% to 70%, with higher rates observed among persons with significant hepatic fibrosis, HCV genotype 3, and exposure to NRTIs didanosine and stavudine[Macías 2012; Sulkowski 2005; Miller 2000; McGovern 2006; Marks 2005]
  • HIV-infected patients receiving ART may be at increased risk for the development of NAFLD, particularly in the setting of obesity
  • Some HIV-1 PIs have been associated with hyperlipidemia and steatosis as well as insulin resistance and diabetes[Riddle 2001; Carr 1999]

Action required